Early Drug Discovery Services

Key Stages in Drug Discovery

The drug discovery process follows a systematic approach to identify, develop, and introduce new therapeutics to the market. The main stages include:

1. Target Identification & Validation - Recognizing a biological molecule (such as a protein or gene) that plays a role in a disease and confirming that modifying this target could have therapeutic benefits.

2. Hit Identification - Screening extensive chemical libraries to find compounds that interact with the identified target. Techniques used include high-throughput screening (HTS), computational (virtual) screening, and fragment-based drug discovery.

3. Lead Optimization - Refining selected hit compounds to enhance potency, selectivity, and pharmacokinetic properties that minimize toxicity while improving drug-like characteristics.

4. Preclinical Testing - Conducting laboratory and animal studies to evaluate safety, efficacy, and optimal dosing while assessing toxicity, metabolic behavior, and pharmacodynamics (the drug’s effects on the body).

5. Clinical Trials (Human Studies) - Clinical trials progress through multiple phases to evaluate safety and therapeutic effectiveness:

   • Phase 1: Small-scale trials (20–100 healthy individuals) to determine safety and appropriate dosage.

   • Phase 2: Mid-sized studies (100–500 patients) to assess efficacy and monitor side effects.

   • Phase 3: Large-scale trials (1,000–5,000+ participants) to confirm effectiveness and track adverse reactions.

6. Regulatory Approval - Submitting comprehensive data to regulatory bodies (such as the FDA or EMA) for review, and upon approval, the drug becomes available for medical use.

7. Post-Market Monitoring (Phase 4) - Observing long-term safety, rare side effects, and real-world effectiveness, and conducting additional research for potential new applications or formulations.

From a drug discovery perspective, potential drug targets are identified by analyzing disease mechanisms and pinpointing biomolecules (proteins, genes, or pathways) that can be modulated for therapeutic benefit. This process involves genomic and proteomic studies, bioinformatics-driven target prediction, functional assays, RNAi and CRISPR screening, and high-throughput screening (HTS) using in vitro, ex vivo, and in vivo platforms. Once identified, targets undergo validation to confirm their role in disease progression and druggability.

Computational modeling plays a critical role in drug discovery by accelerating target identification, optimizing drug design, and predicting drug-target interactions. It enables structure-based drug design (SBDD), ligand-based drug design (LBDD), virtual screening, and molecular docking to identify promising compounds. Additionally, AI-driven simulations and machine learning models help predict pharmacokinetics, toxicity, and drug efficacy, reducing the need for extensive laboratory testing and expediting the discovery process.

In the early stages of drug discovery, the safety and efficacy of a drug candidate are evaluated through preclinical studies, which include:

• In Vitro Testing – Conducted on cell cultures to assess the drug’s biological activity, toxicity, and mechanism of action.

• In Vivo Studies – Performed on animal models to evaluate pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug effects on the body).

• Toxicity Studies – Identify potential adverse effects, including acute, chronic, and genotoxicity assessments.

• Dose-Response Studies – Determine the optimal dose range for therapeutic effects while minimizing toxicity.

If a drug shows promising safety and efficacy in preclinical studies, it progresses to clinical trials for further evaluation in humans.